PrimeRFP SCOUT · Federal Contract Recompete Brief

75D30124P19870Follow-up testing for tumorigenicity and — Bioreliance Corp

Bioreliance Corp holds $440K across 9 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 2 offers. Set-aside status: NONE. Recompete timing centers on the Sep 24, 2026 PoP end — agencies typically plan 12–18 months ahead.

Cdc Office Of Acquisition Services

Awarding office

Bioreliance Corp

Recipient

Sep 24, 2026

PoP end

$249K

Obligated

$249K

Potential

621511

NAICS

Q301

PSC

NONE

Set-aside

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Bioreliance Corp — $90

Contract facts

NONE

Contract number75D30124P19870

AgencyCdc Office Of Acquisition Services

Awarding officeCdc Office Of Acquisition Services

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentBioreliance Corp

CAGE1CPE3

UEIH3KAG9A26K77

NAICS621511

No full NAICS 621511 intel page yet. Browse NAICS intelligence

PSCQ301

Place of performanceDENVER CO

Pricing typeFirm Fixed Price

Extent competedCompeted Under SAP

Related solicitation75D301-24-Q-78224

PoP startSep 26, 2024

PoP end (current)Sep 24, 2026

Obligated$249K

Current value$249K

Potential value$249K

FOLLOW-UP TESTING FOR TUMORIGENICITY AND ONCOGENICITY. is a federal NONE award for Cdc Office Of Acquisition Services held by Bioreliance Corp. Estimated value $249K ($249K obligated). Current period of performance ends Sep 24, 2026. Last award drew 2 bidders. Place of performance: DENVER CO. Related solicitation 75D301-24-Q-78224.

FOLLOW-UP TESTING FOR TUMORIGENICITY AND ONCOGENICITY.

Recompete timing

Public

● Expiring in 17 days

Current PoP ends Sep 24, 2026 (17 days remaining). Agencies typically plan 12–18 months ahead — at 0.6 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Bioreliance Corp — $440K obligated across 9 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$440K · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75D30124P19870?

75D30124P19870 (Follow-up testing for tumorigenicity and) is a Cdc Office Of Acquisition Services award with a potential value of $249K, currently held by Bioreliance Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75D30124P19870?

Cdc Office Of Acquisition Services awarded 75D30124P19870 to Bioreliance Corp (potential $249K).

Who is the incumbent on 75D30124P19870?

Bioreliance Corp is the incumbent with $440K across 9 related awards in SCOUT’s public footprint. The current period of performance ends Sep 24, 2026.

When does Bioreliance Corp’s 75D30124P19870 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 24, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75D30124P19870 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jun 16, 2025